In this episode Dr. Rohit Mehra of University of Michigan discusses the utility of TRIM63 as a diagnostic marker to distinguish MiTF-RCC from other renal tumor subtypes with overlapping morphology. In combination with TFE3/TFEB FISH, TRIM63 RNA-ISH assays can improve the accuracy and efficiency of MiTF-RCC diagnosis.

Associated article: TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma. https://www.nature.com/articles/s41379-021-00803-z